Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;16(7):1365-76.
doi: 10.1111/j.1582-4934.2011.01486.x.

Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Affiliations
Review

Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Morgane Baron et al. J Cell Mol Med. 2012 Jul.

Abstract

Cardiovascular diseases remain an important cause of morbi-mortality. Atherosclerosis, which predisposes to cardiovascular disorders such as myocardial infarction and stroke, develops silently over several decades. Identification of circulating biomarkers to evaluate cardiovascular event risk and pathology prognosis is of particular importance. Microparticles (MPs) are small vesicles released from cells upon apoptosis or activation. Microparticles are present in blood of healthy individuals. Studies showing a modification of their concentrations in patients with cardiovascular risk factors and after cardiovascular events identify MPs as potential biomarkers of disease. Moreover, the pathophysiological properties of MPs may contribute to atherosclerosis development. In addition, pharmacological compounds, used in the treatment of cardiovascular disease, can reduce plasma MP concentrations. Nevertheless, numerous issues remain to be solved before MP measurement can be applied as routine biological tests to improve cardiovascular risk prediction. In particular, prospective studies to identify the predictive values of MPs in pathologies such as cardiovascular diseases are needed to demonstrate whether MPs are useful biomarkers for the early detection of the disease and its progression.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Schematic representation of the mechanisms of MP formation. (A) In quiescent cells, only flippase is active, allowing PS localization in the inner leaflet. (B) Increased calcium concentrations activate floppase and scramblase, and cytoskeleton reorganization. (C) MPs expose PS and contain proteins and nucleic acids from the cells of origin.

References

    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41. - PMC - PubMed
    1. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J. 2010;160:583–94. - PubMed
    1. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48:180–6. - PubMed
    1. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–71. - PubMed
    1. Connor DE, Exner T, Ma D, et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost. 2010;103:1044–52. - PubMed

MeSH terms